Able increasingly un-Able
Executive Summary
President and interim CEO Robert Mauro resigns from Able Labs July 7. Mauro was promoted to succeed former CEO Dhananjay Wadekar, who resigned May 19, as good manufacturing practice concerns forced Able to suspend production of its products and eventually withdraw its NDAs (1"The Pink Sheet" May 30, 2005, p. 23). The firm announced July 8 that it is pursuing a consent decree with FDA and is considering filing for bankruptcy...
You may also be interested in...
Able Labs To Withdraw Seven ANDAs; Data Integrity Concerns Cited
Able Labs "is no longer willing to rely" on the data in some of its approved ANDAs, the generic drug manufacturer said May 23
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.